Targeting Cancer’s Habitat
MSK’s Bold New Project To Help More People Like Bridget

Also inside:
Making Immunotherapy Work for More Patients
The Microbiome and Its Role in Cancer
Meet Tracy Gosselin: MSK’s New Chief Nurse
Dear MSK Community,

We are poised at a pivotal moment in cancer research.

For the past few decades, researchers have focused on identifying gene mutations associated with cancer and have developed highly effective drugs to target them. This revolutionary approach, called precision oncology, has saved countless lives. Yet too many people still die from cancer, and we now know that addressing genetics alone cannot save most of them.

Up to 90% of the 600,000 Americans who will die from cancer this year will die from metastasis, when cells from a primary tumor spread to other parts of the body. Precision oncology cannot cure metastatic cancer because, to our knowledge, there are no gene mutations that specifically drive metastasis.

The next treatment revolution will come from understanding cancer as a systemic disease, rather than a predominantly genetic disease—one that begins in a single location but relies on conditions throughout the body to spread. Just as invasive plants or fish can only thrive in a nurturing habitat, cancer too requires the right conditions to flourish in the body’s complex ecosystem. Immunotherapy, developed at Memorial Sloan Kettering Cancer Center (MSK), already provides an example of how to leverage a component of the patient’s body, the T lymphocytes, to attack cancer.

This issue of MSK News will report on the mission of the new Marie-Josée and Henry R. Kravis Cancer Ecosystems Project, an ambitious program to investigate cancer beyond genetics. This $100 million initiative will explore how tumors interact with the nervous, endocrine, and immune systems; the gut microbiome; and lifestyle factors like stress and obesity.

The research supported by the Kravis Cancer Ecosystems Project is categorized as “basic science”—meaning it seeks to answer fundamental biological questions rather than test therapies in patients. Basic science is anything but simple or ordinary. It unravels how living systems work. This knowledge leads to better ways to predict, prevent, diagnose, and treat disease. Every breakthrough in cancer therapy started out years—even decades—earlier in the bustling lab of a scientist who was curious about an unexplained phenomenon. With a hunch and a hypothesis, basic researchers follow the science wherever it leads. The end results can be spectacular. Without someone asking why our bodies are able to fight off sickness, we would not today have cancer immunotherapy.

Our commitment to basic science distinguishes MSK from all other cancer hospitals conducting research. The investigators at the Sloan Kettering Institute are like artists and inventors, engaged in a fundamentally creative process that doesn’t always progress in a straight line.

This generous gift will give our scientists the freedom they need to take risks and test bold ideas. Their achievements are sure to benefit people with cancer around the world.

Sincerely,
Joan Massagué
Marie-Josée and Henry R. Kravis Foundation Chair
Director, Sloan Kettering Institute

MSK News
Inquiries about MSK News should be addressed to:
Memorial Sloan Kettering Cancer Center
Marketing & Communications
1275 York Avenue
New York, NY 10065
Phone: 212-639-3573
www.mskcc.org

CHIEF MARKETING & COMMUNICATIONS OFFICER
Roxanne Taylor
EDITOR-IN-CHIEF
Ami Schmitz
SENIOR DIRECTOR, EDITORIAL
Katie Sobolik
ASSOCIATE DIRECTOR, EDITORIAL
Andrew Roth
CREATIVE DIRECTOR
Randi Press
ART DIRECTOR
Kristin Glick
ILLUSTRATOR
Samantha Welker
PHOTOGRAPHERS
Chad Hunt (cover photo)
Rick DeWitt
WRITERS
Bill Pierson
Meredith Begley
Julie Grisham
Jim Stallard
Matt Tontonoz
COPY CHIEF
Toni Rumore
CONTRIBUTOR
Alison Irvine

TABLE OF CONTENTS

4
Weeds in the Garden: Uprooting Cancer’s Ecosystem
This new era of cancer research investigates how the disease in certain locations interacts with all the body’s systems. Focusing on cancer’s ecosystem promises to reveal lifesaving insights, especially into metastasis.

9
Making Immunotherapy Work for More People
Symantha Wilson was crushed when chemotherapy quit fighting her lymphoma—and thrilled when immunotherapy beat back the cancer. But why didn’t immunotherapy help more people? MSK researchers are finding answers.

12
Gut Check: The Microbiota and Its Role in Cancer
To help Bridget Anderson overcome leukemia, MSK doctors called upon her own microbiome, the vast ecosystem of microorganisms that live within us, especially the gut. They’re both friend and foe in fighting cancer.

16
School of Fish: What Fish Fins Are Teaching Scientists About Human Melanoma
One woman’s rare melanoma sparked research led by MSK physician-scientist Richard White involving zebrafish. The surprising results could lead to an entirely new treatment approach.

19
Quantum Leap: How MSK Researchers Use New Technology To See Cancer Like Never Before
MSK investigators are leading the way with approaches so bold they are like the difference between “a snapshot and a movie.”

22
PEOPLE OF MSK
Meet Tracy Gosselin, MSK’s New Chief Nurse
MSK’s new nursing executive shares her mantra for leading nurses and listening to patients: “Keep calm and hurdle on.”

Congratulations!
These prestigious honors will be awarded in early June by ASCO, the American Society of Clinical Oncology.
Fumiko Chino, MD, will receive the Science of Oncology Award for his contributions to the diagnosis and/or treatment of cancer.
Craig B. Thompson, MD, will receive the David Karnofsky Award for his contributions to the diagnosis and/or treatment of cancer.
Jedd D. Wolchok, MD, PhD, will receive the David Karnofsky Award for his contributions to the diagnosis and/or treatment of cancer.

Scan the QR code with your smartphone’s camera to read more.
Weeds in the Garden
The Bold New Project To Uproot Cancer’s Ecosystem

When the ambitious effort to sequence all the DNA in the human genome completed its first draft in 2000, scientists and government officials around the world heralded the achievement of the Human Genome Project.

“Wealth without a doubt, this is the most important, most wondrous map ever produced by humankind,” said President Bill Clinton, likening it to the American frontier map created by explorers Meriwether Lewis and William Clark in 1806. “With this profound new knowledge, humankind is on the verge of gaining immense new power to heal.”

Indeed, the Human Genome Project led to many important scientific and therapeutic advances. Thanks to the technology spurred by the project, it eventually became possible to sequence the genomes of tumors, too. Scientists discovered specific changes in the DNA sequence of genes — specific mutations — that transformed normal cells into cancer cells. In turn, this led to the development of drugs that target tumors with these mutations in order to save more lives.

However, two decades later, scientists have also uncovered what genes do not control, and what they cannot explain about health and illness.

The more scientists learn about genetic mutations, the more they are coming to understand that such DNA changes alone do not cause cancer. A recent study of more than 25,000 MSK patients found no single gene that, when mutated, would predict whether a tumor will metastasize to a particular organ.

“Specific mutations do little to explain how individual cancers spread,” says Joan Massagué, Director of the Sloan Kettering Institute and the Marie-Josée and Henry R. Kravis Cancer Ecosystems Project Chair. “It’s all about adaptation of the spreading tumor to the organs it travels to.”

In fact, scientists now know that the same genetic mutation that promotes cancer in one tissue may leave another unscathed, highlighting the need to understand what else is going on.

This need to look beyond genes, to the interactions among genes, cells, tissues, organs — even whole-body systems — is the mission of the newest scientific initiative from Memorial Sloan Kettering Cancer Center (MSK): The Marie-Josée and Henry R. Kravis Cancer Ecosystems Project.

“It is for us, as scientists and physicians, a watershed moment in cancer research,” says Dr. Massagué, who will oversee the project. “We are shifting the focus from mutant genes in the context of cancer genomes — a staple of research over the past decade and a great source of therapeutic as well as diagnostic insights — to a focus on cancer cells in the context of biological ecosystems.”

As its name implies, the Kravis Cancer Ecosystems Project will galvanize a more global and systemic approach to cancer research than has previously been undertaken, with the aim of tackling the most difficult remaining cancer challenges, including that of metastasis. But first, what exactly do scientists mean by the cancer ecosystem?

Cancer’s Habitat
Consider the ecosystem that we are all more familiar with — the one outside our doors. That ecosystem is made up of the plants and animals that make their home there. It also includes the food they consume, the elements and minerals that are recycled when organisms die, and the nonliving parts of the environment (like precipitation and temperature) that affect the climate. The parts of an ecosystem are all inter-connected; changing one part can have a cascading effect on the others.

Likewise, tumors are part of a wider ecosystem that determines how they grow. They are affected not only by the genes they carry but also by the environments they encounter as they develop and spread. Cancer is not just a disease of a tumor but a disease of the whole organism that has it.

More than a century ago, the English doctor Stephen Paget proposed the “seed and soil” hypothesis to explain how cancer spreads. The idea was that cancer cells are like seeds that require a fertile and compatible soil in order to grow.

The Kravis Cancer Ecosystems Project takes an even wider, more comprehensive view. If a tumor is like a weed, then the weed’s ecosystem includes the soil the weed finds itself in, the nutrients that flow in and out of that soil, the competition from nearby plants that also require those nutrients to grow, the sunlight that warms and feeds the plant or is blocked by trees, the predatory insects that feed on the weed’s leaves, and even the animals that help disperse seeds. All these factors influence whether the weed thrives or succumbs to heartier vegetation.

“Joan Massagué, Director of the Sloan Kettering Institute, will oversee the new Kravis Cancer Ecosystems Project.

Joan Massagué, Director of the Sloan-Kettering Institute, will oversee the new Kravis Cancer Ecosystems Project.

Continued on page 8

Read more stories online: mskcc.org/spring-2022

4 | MSKNews

5 | MSKNews
Understanding the Cancer Ecosystem

There are many similarities between nature’s ecosystem (left page) and your body’s ecosystem (right page). Think of a tumor like a weed, whose growth depends on many factors.

**Energy**
Plants obtain their energy from the sun, while tumors burn glucose and fats for energy.

**Dispersal**
Tumor cells continually break off from a primary tumor and spread to other locations, like plant seeds dispersed by wind.

**Growth**
Hormones from the endocrine system and messages from the nervous system provide growth signals for the tumor, in the same way that plant hormones trigger germination.

**Nutrients**
Tumors get nutrients from blood vessels much like roots get nutrients from the soil.

**Microbiome**
Our digestive system contains microbes that help us digest nutrients, much the way fungi and other decomposers recycle nutrients in a forest.

**Removal/Destruction**
Predatory insects eat and may kill a growing plant, similar to how macrophages and other immune cells attack a growing tumor.

**Competition**
Other plants and animals compete with the weed for space and resources, just as normal cells compete with a tumor.

**Microenvironment**
The pH of the soil, like that of the tumor microenvironment, can affect growth.

**Temperature**

**Precipitation**

**Photosynthesis**

**Respiration**

**Decomposition**

**Weed**

**Nervous System**

**Endocrine System**

**Immune System**

**Circulatory System**

**Digestive System**

**Tumor**

**Microenvironment**
The pH of the soil, like that of the tumor microenvironment, can affect growth.
The more scientists understand about the cancer ecosystem, the more they can begin to think about therapies designed to block parts of it — depriving a pesky weed of the opportunity to take over your garden.

Memorial Sloan Kettering Cancer Center (MSK) is grateful to Alan and Sandra Gerry and Marc and Jennifer Lipschultz for their support of metastasis research at MSK.

Targeting the Ecosystem

The more scientists understand about the cancer ecosystem, the more they can begin to think about therapies designed to block parts of it — depriving a pesky weed of the opportunity to take over your garden.

In concrete terms, that means understanding more about several key biological processes. Perhaps the most immediate is understanding cancer’s metabolism: how it takes in and uses nutrients for energy and building blocks. Scientists at MSK, including cell biologist Lydia Finley and cancer biologist Craig B. Thompson (Douglas A. Warner III Chair), are learning that cancer cells can adapt their metabolism in ways that give them the unusual capacity to reproduce endlessly. Not only that, but the particular metabolic pathways they use can alter their identity in ways previously unrecognized — for example, making them more like stem cells, with the potential to develop into tissue samples.

Cancer biologists Joan Massagué, Adrienne Boire (Geoffrey Beene Junior Faculty Chair), and Karuna Ganesh (Josie Robertson Investigator) are dedicated to studying the deadly process of metastasis and the question of how cells that are shed from tumors can make their way in often hostile new environments. They are learning that metastatic cells co-opt the normal processes of wound healing to take root in new organs. SKI scientists Justin Perry, Alexander Rudensky, and Philipp Niethammer are determined to understand the role of inflammation in nurturing tumor growth, while cancer biologist Scott Lowe (Geoffrey Beene Chair) and computational biologist Dana Pe’er (Alan and Sandra Gerry Chair) are exploring the role of the tumor stroma in doing the same.

Figuring out how cancer hijacks normal development pathways is the mission of developmental biologists Anna-Katerina “Kat” Hadjantonakis (Alfred P. Sloan Chair), Charles Sawyer’s (Marie-Josee Kravis and Henry R. Kravis Chair in Human Oncology and Pathogenesis), and Danwei Huangfu. And that’s just the tip of the iceberg.

In fact, the more scientists learn about cancer, the more they are realizing that nearly every system in the body — from the endocrine system to the nervous system to the digestive system — can affect cancer growth. With that knowledge comes the hope that each of these systems could one day become a target for cancer therapies.

“Immuno-oncology has shown us the tremendous power of treatments that leverage components of the cancer ecosystem to attack tumors,” Dr. Massagué says. “We believe that new findings to emerge from the Kravis Cancer Ecosystems Project will allow us to leverage other components of the ecosystem to the same end.”

And so a new era begins.

Making Immunotherapy Work for More People

Symantha Wilson knows she is one of the lucky ones. The 26-year-old Long Island resident was nearing the end of a six-month chemotherapy regimen for stage 2 Hodgkin lymphoma last June. The treatment had been very effective, wiping out most of the cancer cells. But with just over a month left in her regimen, she was crushed to learn that her blood cancer was growing resistant to the therapy.

“My cancer was increasing even as I was getting chemotherapy,” she says. “Then to fast-forward six weeks and not have cancer at all — thanks to science and God’s help — it was truly amazing.”

Symantha Wilson

Why Doesn’t Immunotherapy Work for More Patients?

Immunotherapy has undoubtedly saved many people. But the sobering truth is that cases like Symantha’s are still the exception. Far too often, immunotherapy does not work. Checkpoint inhibitors fail to be effective in up to 80% of patients. The success rate is not much better with chimeric antigen receptor (CAR) T cells, which engineer a patient’s own cells to attack the cancer. CAR T therapies are difficult to administer and so far, have only worked for certain blood cancers.

“To be so close to thinking that I beat it and then get that news was devastating,” Symantha says. “I felt like, ‘Maybe this is it for me. I don’t stand a chance.'”

Her doctor on Long Island referred her to Memorial Sloan Kettering Cancer Center (MSK), where she joined a clinical trial led by medical oncologist Alison Moskowitz. The study was testing a drug that works by harnessing the immune system to fight the cancer. Doctors would combine this drug, called pembrolizumab (Keytruda™), with a different chemotherapy regimen and then perform a stem cell transplant.

Pembrolizumab is known as a checkpoint inhibitor. It works by releasing a natural brake that the immune system places on powerful immune T cells so they don’t accidentally attack normal cells. Cancer cells hide from attack by tripping the brake, hoping to fool T cells into believing they are normal. But checkpoint inhibitors release the brake, allowing the T cells to activate, recognize, and attack tumors.

Symantha began the treatment in September. After only six weeks, her cancer was undetectable, and she was able to have the stem cell transplant. Four months later, she remains cancer-free. Her doctors say her outlook is excellent.

“It was so scary and discouraging to hear my cancer was growing even as I was getting chemotherapy,” she says. “Then to fast-forward six weeks and not have cancer at all — thanks to science and God’s help — it was truly amazing.”

Symantha Wilson

“‘It was so scary and discouraging to hear my cancer was growing even as I was getting chemotherapy. Then to fast-forward six weeks and not have cancer at all — thanks to science and God’s help — it was truly amazing.’

—Symantha Wilson

Read more stories online: mskcc.org/spring-2022

8 | MSK News

9 | MSK News

Memorial Sloan Kettering Cancer Center (MSK) is grateful to Alan and Sandra Gerry and Marc and Jennifer Lipschultz for their support of metastasis research at MSK.

Continued from page 5
Santosha Vardhana has discovered that T cell behavior is greatly affected by nutrients in the surrounding environment, an important insight into the ecosystem of cancer in the human body.

Sadly, many people initially respond to immunotherapy only to find the benefits are fleeting. “One tragic element of the immunotherapy revolution is how it changes the expectation for even some of our very sick patients,” says MSK physician-scientist Santosha Vardhana (Jose Roberson Investigator), who treats people with lymphoma. “Many of them experience a brief wispy of promise. They just start to experience the possibility of joy and then have it taken away.”

When Immune Cells Stop Working

The immune system does its best to fight cancer cells naturally—T cells sense danger, flock to tumors, even invade them. But then they lay down their arms. Something causes the T cells to become dysfunctional. They enter an exhausted state in which they can no longer renew and give rise to cells to keep the attack going. It’s called “T cell exhaustion.” Immunotherapy seeks to boost the immune system to keep up the fight, but too often, it doesn’t work.

MSK researchers, including Dr. Vardhana, are trying to unravel the mystery. It’s proving to be extraordinarily complex. “We haven’t really understood how or why T cell exhaustion happens,” Dr. Vardhana says. “Because of that, we don’t really have good strategies that reverse it, which is critical to making immunotherapy treatments work for more people.”

Thinking Outside the Box

Also keenly interested in understanding T cell exhaustion is Andrea Schietinger, an immunologist in the Sloan Kettering Institute (Catherine and Frederick R. Adler Chair for Junior Faculty) and former Josie Robertson Investigator. In 2017, her lab reported in Nature that T cells become dysfunctional through successive waves: When T cells enter tumors, they quickly lose their ability to kill cancer cells, but their fate is plastic — there is an early win- dow in which they can still be reactivated. But with time, the T cells become exhausted and settle into a fixed state in which they cannot be reprogrammed. Presumably this is a checkpoint inhibitors work when they catch the T cells early enough — in their plastic state.

But Dr. Vardhana says it’s becoming clear the drugs don’t actually reverse T cell exhaustion. Instead, checkpoint inhibitors seem to “extract the remaining juice” out of exhausted T cells. Furthermore, the drugs seem to work only if the tumor has a lot of mutations that the T cells can attack, or if the tumor is small enough that the T cells don’t have as much work to do.

In 2019, Dr. Schietinger discovered something even more surprising about T cells in tumors: They enter the exhausted state to save themselves. They stop fighting to avoid becoming overstimulated and dying. It’s about their own survival, Dr. Schietinger reported in a study published in Nature.

All together, these findings show, simply “taking the brakes off” the immune system with checkpoint inhibitors won’t work. “We need to look at everything causing T cell exhaustion and find ways to prevent or undo it,” Dr. Schietinger says.

How the Ecosystem Could Help T Cells Keep Fighting

MSK scientists are laser-focused on understanding cells in the ecosystem around tumors, because those surrounding cells send various signals to the T cells. Investigating how those signals are then processed or metabolized by the T cells is the focus of research funded by a prestigious grant received by Dr. Vardhana — the 2022 Damon Runyon Cancer Research Foundation-Rachleff Innovation Award. He is studying lung cancer and mesothelioma, because in both diseases there is a buildup of fluids and cancer cells in the pleura, a thin layer of tissue between their lungs and the chest wall and the lung.

“We focused on these cancers because we wanted to be able to sample the environment a T cell is living in,” he says. “It’s really hard to get samples from most tumors, which are tightly packed, but the pleura is an off-the-beaten-path very clean way to look at the environment where T cells have to live and function as they try to respond to tumors.”

Much to their surprise, his team found that T cells in the pleural fluid are not capable of mounting an immune response. Once they enter this space, they are instantly told to stand down, so immunotherapies don’t work. This suggests that certain ecosystems in the body may naturally suppress all T cell activity.

“The fundamental decision a T cell has to make is whether to turn on and attack when it detects something that seems to be foreign, like a cancer cell,” says Dr. Vardhana. “We’re learning that the environment around the T cell can fine-tune its behavior.”

Dr. Vardhana’s lab has found evidence that T cells can change their entire state — becoming dormant or active — based on how they metabolize nutrients obtained from their environment. Therefore, adding or depleting nutrients in their ecosystem could theoretically activate T cells to attack the cancer.

“We’re excited to probe this further because it could have broad implications for improving immunotherapy in many cancers,” he says.

Learning From Autoimmune Disease — When T Cells Go Into Overdrive

Another way to combat T cell exhaustion could be changing the T cells themselves. In a bold study launched four years ago, Dr. Schietinger’s team took a cue from immune cells in autoimmune diseases, where the immune system goes into overdrive and attacks the body’s own organs, relentlessly. Dr. Schietinger asked: “What is it about autoreactive T cells that they never give up? Why don’t they get exhausted?”

“We thought if we could figure out how autoimmune T cells are programmed, we could take that information and apply it to tumor-specific T cells to make them more effective cancer killers,” she says.

It was an out-of-the-box idea. To pursue this ambitious research project, Dr. Schietinger also received a prestigious grant — the National Institutes of Health Director’s New Innovator Award in 2017. Her team studied mice that spontaneously develop type 1 diabetes, an autoimmune disease where T cells destroy insulin-producing cells in the pancreas. The surprising findings were published in 2021 in Nature: There are stem-like T cells in lymph nodes that can generate billions of new highly functional killer T cells, so they are constantly resupplied. That’s why the T cell destruction of the pancreatic cells never stops.

“We think about the road we have ahead of us.”

Santosha Vardhana

Andrea Schietinger

“T his was quite a breakthrough for me as a tumor immunologist, because we can take this information and think about how we can potentially engineer stem-like T cells and their environment for the fight against tumors.”

Dr. Schietinger’s and Dr. Vardhana’s work is made possible by the generosity of the Carson Family Charitable Trust, Pershing Square Sohn Cancer Research Alliance, Gateway for Cancer Research, Cancer Research Institute Lloyd Old STAR Award, AACR Bristol Meyers Investigator Award, and other members of the MSK donor community.

“ ‘We haven’t really understood how or why T cell exhaustion happens, which is critical to making immunotherapy work for more people.’ —Santosha Vardhana

“ ‘This is quite a breakthrough for me as a tumor immunologist, because we can take this information and think about how we can potentially engineer stem-like T cells and their environment for the fight against tumors.’ —Andrea Schietinger

Read more stories online: mskcc.org/spring-2022
Bridget Anderson had been looking forward to attending a concert at the Red Rocks Amphitheatre in Colorado with college friends. But a few days before her trip, she'd gone to her doctor in Newark, New Jersey, complaining about fatigue. Blood tests revealed devastating news: She had acute lymphoblastic leukemia. "I was admitted on my 45th birthday," she says. "Talk about putting the aging process in perspective."

She needed a transplant to replace her own blood stem cells, which were being destroyed by the leukemia. She was given a 50% chance of survival. She was also given the opportunity to participate in a study led by infectious disease expert Ying Taur testing the impact of manipulating the ecosystem of her gut. There is growing evidence that patients having stem cell transplants benefit from fecal microbiota transplants — known more commonly as poop transplants.

"When I learned I'd been selected for the last group of the trial, I told my boyfriend, Charlie, that I never in a million years thought I'd be rooting to have my feces put back inside me," Bridget remembers.

This procedure may sound off-putting, but it's a cutting-edge way to manage a critical system in the body. The microbiota is the ecosystem of microorganisms that swarm our gut, live on our skin, and thrive in our respiratory airways. This ecosystem plays a vital role in maintaining good health. In the gut, these bacteria train our immune system and help us obtain nutrients from our food, but they can also cause inflammation and suppress the immune system.

For these reasons, scientists at MSK are searching to uncover the role the microbiota plays in cancer. Researchers throughout the institution are focused on how managing the microbiota can improve patient care as well as someday even potentially prevent certain cancers, like colorectal cancer, from ever developing in the first place. We've learned the microbiota can also impact how well a patient responds to treatments with immunotherapy. That makes sense, because about half of your immune cells live in your gut and are in contact with your microbiota.

"My doctors explained that when you have any kind of stem cell or bone marrow transplant, the treatment kills a lot of the healthy bacteria that you need in your gut," Bridget says. "They thought that storing it and later putting it back might reduce some of the side effects from the transplant. I thought, 'Why not? I'll give it a try.'"

Before she began her transplant in October 2015, a sample of Bridget’s stool was collected and frozen. Later, after she received chemotherapy and infusions of umbilical cord blood to replace her own blood stem cells, her stool was thawed out and returned to her body.

Always an optimist, she says, "I never once thought my cancer treatment would not be successful."

A Treasure Trove of Data on Transplant Patients

For more than a decade, MSK has been at the forefront of studying gut microbiota in people receiving stem cell and bone marrow transplants (BMTs). This initiative has been led by physician-scientist Marcel van den Brink, Head of the Division of Hematologic Malignancies and a member of the Immunoology Program at the Sloan Kettering Institute (SKI).

Dr. van den Brink and his team have now amassed biological samples and comprehensive records for more than 1,400 patients. "We have a wealth of clinical data on these patients, including every drug they took and, in some cases, even what they ate," says Dr. van den Brink (Alan N. Houghton Chair). "Having all of these details allows us to do research that wouldn't be possible anywhere else."

Scientists have learned that the microbiota can be thrown out of balance by the large doses of antibiotics given to patients to protect against infections while their immune cells are wiped out during a BMT. They've also discovered that patients with a less diverse microbiota are more likely to suffer graft-versus-host disease (GVHD), a potentially deadly side effect in...
Infectious disease doctor Ying Taur led a study looking at all the benefits of fecal microbiota transplants.

which the donor’s immune cells attack the recipient’s healthy tissues.

In The New England Journal of Medicine in 2020, Dr. van den Brink and his colleagues reported that the diversity of the gut microbiota can predict a patient’s survival after a BMT. The research — a multicenter study involving cancer centers in Germany, Japan, and North Carolina — showed that the link between bacteria in the gut and patients’ outcomes is important across the globe.

Figuring out which gut bacteria matter the most could be a game changer: It might help predict which patients will benefit from certain types of cancer treatment and improve care for more of them by adjusting their microbiota.

Microbes and the Immune Cells: A Complex Relationship

Teasing apart the complexity of the microbiome requires a lot of expertise and computing power. SKI systems biologist Joao Xavier develops mathematical models to untangle this complexity. In a landmark study in Nature in November 2020, Dr. Xavier and his colleagues showed for the first time how the gut microbiota directly shapes the makeup of the human immune system. “During BMTs, the immune system and the microbiota are both damaged,” Dr. Xavier says. “Being able to track their parallel recovery gives us a unique opportunity to test the associations between the two of them.”

Understanding how the microbiota teaches immune cells is the focus of research by SKI immunologist Gretchen Diehl. “A lot of what I’m interested in is how specific microbes regulate the immune system,” says Dr. Diehl (Catherine and Frederick R. Adler Chair for Junior Faculty).

Using mouse models, her team has discovered that gut bacteria travel to the thymus — the organ that makes immune cells called T cells. The bacteria train the cells to distinguish between friend and foe. Their research was published in Nature in May 2021.

The gut microbiota’s connection to the immune system may offer clues explaining how colorectal cancers develop, including those in younger patients. “It’s possible that certain microbes activate signaling in the lining of the gut, which could promote cancer,” Dr. Diehl says. “It’s important for us to understand the more mechanistic interactions between microbes and the intestine to get at why this might happen.”

Bridge’s Poop Transplant

Bridge’s fecal microbiota transplant was autologous, which means that she was given back her own microbiota. It had been stored at the start of the study, before she got her cord blood transplant. Studies at other hospitals have looked at the benefits of transplanting donor stool. But because people having BMTs are so susceptible to infections, MSK researchers wanted to take a safer route and avoid transferring potentially dangerous strains that could be present in donors.

“The gut microbiota is kind of a black box,” Dr. Taur says. “We don’t always know exactly what it contains or which individual species will be the most beneficial.”

In 2018, Dr. Taur and his colleagues published results in Science Translational Medicine that confirmed autologous fecal transplants help restore a healthy microbiota. A preliminary analysis suggests that people who received the fecal transplant after their BMT had lower rates of viral infections and graft-versus-host disease. “Viral infections and GVHD are the top two complications that BMT patients face, and both are related to the immune system,” Dr. Taur says. “We know that the immune system does a better job of rebuilding itself in the presence of a healthy, diverse microbiota.”

Six months after her fecal transplant, Bridge learned that her gut had been successfully reconstituted by healthy bacteria. Having her ecosystem back in balance helped her through her transplant journey, which took months. “Throughout the whole process, I really didn’t have any serious infections,” she says.

MSK researchers are looking at other ways to keep a healthy balance of microbes in people having BMTs. There’s an experimental microbiota pill being tested by hematologic oncologist Doris Ponce and medical oncologist Miguel Angel Perales, Chief of the Adult BMT Service. MSK physician-scientist Jonathan Peled played an important role in the design of this pill and the trial. Investigators are also studying whether more careful use of antibiotics during the BMT process can protect healthy microbes and prevent harmful ones from taking hold.

It’s been almost seven years since Bridge had her transplant. She’s healthy and grateful to Dr. Taur and hematologic oncologist Juliet Barker, her transplant doctor. In August 2021 she married Charlie Gerstung, the boyfriend who stayed by her side throughout her treatment.

She also finally made that trip to the Red Rocks Amphitheatre. “Amongst the mountains of the Colorado night sky on a summer night,” she said a group of BMT patients, “I closed my eyes and looked up to God and the universe and said, ‘Thank you.’ “

“I closed my eyes and looked up to God and the universe and said, ‘Thank you.’ ”

—Bridge Anderson

Microbiome research at MSK is supported by Anthony B. and Judith W. Evnin and the Tow Foundation. Dr. van den Brink’s microbiome research is supported by the Peter and Susan Solomon Family Foundation and the Paula and Rodger Riney Foundation.
As a melanoma researcher, Dr. White was intrigued by this patient’s case, particularly when genetic testing revealed that the woman’s tumor had an unusual genetic alteration.

“Melanomas that occur on the face, trunk, or back usually have DNA alterations in a gene called BRAF,” Dr. White says. “But this patient had an alteration in a gene called CRKL [pronounced ‘crackle’].”

Dr. White was curious about why the same type of cancer — melanoma — would be associated with different alterations in different parts of the body. Why do some DNA changes cause cancers to take root in the hands and feet, but not elsewhere? Why do most skin cancers never appear on the hands and feet? And what does location have to do with the ability of a genetic change to cause cancer?

To get to the bottom of the mystery, he and an MD-PhD student in the lab, Joshua Weiss, decided to do some experiments using their favorite model organism: zebrafish.

Zebrafish are translucent, which means they are a great tool for studying cancer because you can actually see tumors forming beneath the scales. They are also easy to genetically engineer.

“We can take a cancer gene from a human and put it into a fish, and the fish will get cancer — allowing us to really understand how these genes work,” Dr. White explains.

For this study, Dr. Weiss engineered zebrafish to contain either extra CRKL genes or a mutant BRAF gene. Then, he monitored them for about a year. Along the way, he noticed something intriguing: Most of the fish with a BRAF mutation developed tumors on their body. Those with CRKL developed tumors on their fins.

It was a mirror of what they saw with their patient — only instead of a foot it was a fin.

That initial observation was the start of a five-year-long research investigation that would eventually lead to a paper published in *Nature*. It may also lead to an entirely new treatment approach.

“Not only can a DNA mutation behave differently depending in the type of cell it finds itself in, but different parts of the body are susceptible to different mutations,” Dr. White says.

**Treating the Location, Not the Cancer**

The typical way of treating cancer is to target a mutated gene with a drug — for example, when a person with a BRAF mutation is prescribed the targeted drug vemurafenib. But if the ability of genes to cause cancer also depends on location, then...
Quantum Leap
How MSK Researchers Use New Technology To See Cancer Like Never Before

To study a complex ecosystem, researchers often deploy an armada of high-tech tools.

On the African savanna, for example, drones track migrating elephants. Infrared sensors spy on leopards as they prowl at night. And DNA tests reveal the unique genetic fingerprints of plant and animal species. Analyzing all this data requires enormous computing power.

And so it is for MSK researchers, as they investigate the hugely complex ecosystem of cancer in the human body. To advance their understanding, MSK scientists are pushing the frontier of what technology can see, on a scale that stretches from the atom to the entire human organism.

What they are discovering is already changing how MSK — and the world — treat cancer.

Guided Tour
“This is an image that I probably couldn’t have shown you a year ago,” Anna-Katerina “Kat” Hadjantonakis tells an audience on a February afternoon. She is the Chair of Developmental Biology at the Sloan Kettering Institute (SKI) and Alfred P. Sloan Chair and is leading a guided tour through a 3D image of a mouse embryo.

“The mouse tissue is dense and opaque,” says Dr. Hadjantonakis. “But the resolution of the imaging is so high that we can zoom in to see any individual cell in the context of the tissue surrounding it.”

That means, she explains, that “we can study cells not just one at a time, but by the tens of thousands. We can see all the cells that make up an organ at the same time.”

She continues that “the tissues of our body are infiltrated with blood vessels and lymphatic vessels and the immune system, to name just a few. They are very complex. Now we can look at all these different features at once — and over time.”

Supporters of Richard White’s research include the Melanoma Research Alliance, Pershing Square Sohn Cancer Research Alliance, and Mark Foundation for Cancer Research.

Lorenz Studer’s research is supported by Aligning Science Across Parkinson’s (with The Michael J. Fox Foundation for Parkinson’s Research) and the JPB Foundation.

SKII developmental biologist Lorenz Studer is creating tools that could one day aid personalized medicine.

“it’s very rare for a basic laboratory finding to have immediate therapeutic implications, but this one does. Not only for this patient, but for other patients as well.”

—Richard White

It might be possible to blunt cancer development by blocking location cues.

“It leads to the interesting idea that instead of treating the oncogene — or the tumor even — we can treat patients who have these tumors based on their anatomic location.”

To identify potential “location” drugs, Dr. White’s team is taking advantage of a technology developed with Dr. Studer for the previous study. Scientists take genes from a patient’s tumor, put them into human embryonic stem cells, and grow these stem cells into skin cells to create a custom-made model of the patient’s tumor in a dish.

With this model, the scientists can then test a battery of chemicals on the cells to see which might make good medicines. Once they find candidate drugs, they can go back to the fish and test them in a living animal to see if they are safe and effective.

That’s exactly what they are doing for the patient from five years ago. Using these innovative methods, they have found — and are now testing — a handful of drugs that may be effective at treating that woman’s CRKL tumor.

Your Own Ecosystem
The melanoma patient who sparked Dr. White’s research doesn’t have a need for these drugs right now. She is still doing well following surgery to remove her original tumor. But should the cancer relapse, these drugs will be there waiting for her.

Dr. White hopes that this approach to drug development will become a reality for more and more patients. It would mean the beginning of a new era of personalized medicine. No longer only available off-the-rack, drugs would be tailor-made and tested for you, depending on your personal ecosystem.

It’s very rare for a basic laboratory finding to have immediate therapeutic implications, but this one does. Not only for this patient, but for other patients as well.”

—Richard White
Movie Magic

This breakthrough is achieved by microscopes that look nothing like the device many people peered through in high school.

The 3D mouse image was produced by the Bruker Luwe-Moi IV SMX light-sheet microscope. It works by taking thousands of scans using a sheet of laser light at different depths, and from different positions, and then digitally compiling them into a single 3D image. Dr. Hadjantonakis compares the resulting image to a movie — while older technologies produced snapshots.

"Imagine a 90-minute movie on Netflix," she says. "If you were only given one snapshot of the movie every five minutes, it would be very difficult to piece together the story." With the new technologies, however, "we can look at all the actors together and see how they interact. And we can look at them over time to see how the story unfolds. That means we can make new insights and raise new questions."

As a developmental biologist, one of the big questions that fascinates Dr. Hadjantonakis is the process by which normal cells grow and work together to build organs — and how those processes are disrupted or hijacked in diseases like cancer.

She points out that "tumors are not entirely composed of cancer cells. They are actually an integration of tumor and normal cells. It’s really important that we understand how both normal and cancer cells arise — and how they interact in a tumor."

The goal, she says, "is to understand what’s normal, what’s going wrong in disease, and how we can intervene." Long-term, the insights gained into how single cells develop into tissues may provide the ability to "repair, replace, or regenerate an organ damaged by cancer, so we can restore patients to their normal lives."

Finding Vulnerabilities

To capture these “very small and very fast interactions,” the Zeiss Elyra microscope casts light into a pattern like a crisscross lattice, then rapidly moves the pattern and combines all the resulting images to extract a higher-resolution image.

Having revealed a critical mechanical dimension to T cell killing, Dr. Huse’s research is now investigating the implications. "It turns out that metastatic cancer cells need to physically stiffen in order to colonize new organs. In collaboration with Joan Massagué’s group, we recently showed that stiffening makes the cancer cells more vulnerable to T cells."

This new type of biomechanical vulnerability could perhaps be given a boost by medicine in the never-ending arms race between the immune system and cancer. (You can learn more about Memorial Sloan Ketting Cancer Center efforts to strengthen the immune system to fight cancer on page 9.)

An Intersection of Revolutions

This new world of research relies on one of the fastest-growing fields in biomedical science: computational biology and related disciplines. Dr. Hadjantonakis points out that it takes “very sophisticated computational methods to analyze all the data we’re generating — a computer may extract patterns that I may not see.”

That’s where computational biologists come in, like Christina Leslie, a member of the SKI Computational and Systems Biology Program. Trained as a mathematician, she helped develop crucial artificial intelligence and machine learning methodologies that make sense of the enormous data sets generated by research into cancer genetics and the human genome — the blueprint of genetic instructions.

Today, Dr. Leslie’s field will be just as important in unlocking the secrets hidden in the mountain of data generated from the focus on the cancer ecosystem. She says: “I think we’re at the intersection of multiple revolutions. There’s a revolution in single cell genomics. There’s a revolution in genome editing, which allows us to study the consequences of genetic changes. There’s a revolution in data science. And it’s all moving really fast.”

Investment for the Future

Staying ahead of the revolution is the purpose of the Research Technology Transformation (RTT) initiative at SKI, which relies on generous support from donors, including the Friedman Family Foundation and Cycle for Survival. The RTT seeks to get the best new technology into researchers’ hands quickly and share resources when possible. That provides a competitive edge that is essential to recruit and train the best and brightest of tomorrow.

Dr. Hadjantonakis says: “I don’t think we would have been able to bring in these instruments that will allow us to make these scientific advances without the RTT. It puts us five years ahead of the curve of other institutions.”

Several high-profile projects in the pipeline include:

• Triple Quadrupole Mass Spectrometry, led by Derek Tan (Eugene W. Kettering Chair), which will cut sample processing time from 10 minutes to as little as six seconds.

• Expanding the Single-cell Analytics Labs (SAILs), led by Dana Pe’er (Alan and Sandra Gerry Chair) and Ronan Chaligné.

• Organoid Innovation Lab, which will create disease models using patients’ own cancer cells, under the direction of Scott Lowe (Geoffrey Beene Chair), Lorenz Studer, and Charles Sawyer (Marie-Josée Kravis and Henry R. Kravis Chair in Human Oncology and Pathogenesis).

Together, all these resources will search for vulnerabilities in the hugely complex ecosystem of cancer in the human body, another major step forward in the effort to ensure that cancer is no longer the king of the jungle.

Christina Leslie is a member of the SKI Computational and Systems Biology Program.
Meet Tracy Gosselin  
MSK’s New Chief Nurse

Tracy Gosselin says she was taken by surprise when she got the call asking her to consider applying for the top nursing job at Memorial Sloan Kettering Cancer Center (MSK).

“I laughed and said, ‘I can give you lots of names,’” she recalls. After careful thought and consultation, she ultimately decided to apply. She got the job not only because she had the experience; she also has the heart and soul of an oncology nurse.

Dr. Gosselin joined MSK in November 2021 as Senior Vice President, Chief Nurse Executive, and Chair of Nursing. Her credentials are impressive — PhD, RN, ACCN, NEA-BC, FAAN — plus 28 years in nursing at Duke University Hospital. But Dr. Gosselin says she is stepping into the shoes of a luminary in the field — Elizabeth McCormick. Under her leadership, MSK’s nursing staff twice received Magnet® recognition, the nation’s highest honor for exceptional nursing care.

“It’s really about building upon the excellence that’s already here,” Dr. Gosselin says, taking a sip of her Diet Coke. It’s 3:30 p.m. on a Friday, and she is just sitting down to lunch. After nearly 30 years as a nurse, a busy schedule doesn’t faze her.

A Calling to Cancer
She grew up in Sutton, Massachusetts, 50 miles outside Boston, and says she found her passion for nursing when she was a teenager volunteering at a local hospital.

Delivering flowers to patients, rocking babies in the nursery, and assisting nurses on nonclinical tasks focused her ambition and taught her the value of human connection. She called it an honor “being present and learning how people navigated whatever it was that brought them in.”

She was inspired to enroll in a five-year program at Northeastern University. When she started to care for people with cancer, she knew she had found her vocation. “I loved getting to know their stories and who they were as people,” Dr. Gosselin says.

To the surprise of no one in her life, she received multiple job offers upon graduating. She chose Duke, which was opening a new solid tumor oncology unit that emphasized continuity of care: one nurse providing top-to-bottom care for a small group of patients. Dr. Gosselin packed her things and moved 700 miles south. North Carolina, she admits, took some getting used to.

“I thought I could ride my bicycle to work because in Boston, there were buses, there was the T, and people knew how to take care of snow,” she says with a laugh. “The recruiter took one look at me and said, ‘You need to get a car!’ ”

‘Keep Calm and Hurdle On’
But just as she defended her PhD, she got heartbreaking news: Her father was diagnosed with stage 4 gastroesophageal cancer. Suddenly, she saw cancer from the other side of the bed, as a patient’s loved one. Sometimes, Dr. Gosselin had trouble switching off her “nurse brain.”

“I will never forget what the hospice physician told me,” she says. “He said, ‘Tracy, you just need to be a daughter right now.’ ”

Her father’s illness and death taught her the importance of simply sharing in her patients’ stories. They love walking in Central Park, going to museums, and seeing Broadway shows. It’s an exciting new chapter for Dr. Gosselin and one she never imagined. “Growing up, I didn’t know much about cancer,” she says. “But oncology chose me, and I keep choosing it, over and over again.”

‘Oncology Chose Me’
When she started, she set out to meet as many as possible, spending time in inpatient units and at each of MSK’s seven regional locations. “I think it’s important to see people and thank them, because it’s not easy,” she says. “There’s a big push around self-care, but people want more than that. People want to be seen, heard, and valued for their contributions.”

Long-term, her priorities are to recruit top-tier talent and to ensure care is accessible to people outside of New York City. She’s also looking forward to mentoring the next generation of MSK nurses. She says, “You just try to pay it forward for what other people did for you early on.”

When the workday ends, she enjoys exploring the city with her husband, John. They love walking in Central Park, going to museums, and seeing Broadway shows. It’s an exciting new chapter for Dr. Gosselin and one she never imagined. “Growing up, I didn’t know much about cancer,” she says. “But oncology chose me, and I keep choosing it, over and over again.”

Dr. Gosselin’s pups, Bella and Luna, are sisters who were rescued from Puerto Rico after back-to-back hurricanes.
In 2014, the Kravises made a gift to establish the Marie-Josée and Henry R. Kravis Center for Molecular Oncology (CMO), a first-of-its-kind research powerhouse dedicated to understanding the molecular drivers of cancer. With the couple’s support, the CMO developed the first FDA-authorized tumor-sequencing test, MSK-IMPACT®, which can detect cancer-associated mutations in hundreds of genes. This breakthrough allows doctors to match patients with drugs that can effectively target and treat their cancer. And in just a few years, the CMO’s work has led to the creation of many life-changing therapies for people with cancer.

But genes are only one piece of the cancer puzzle. Once again, the Kravises, whose philanthropy is informed by decades of experience in finance, analysis, and strategic planning, are helping MSK’s doctors and scientists accelerate progress in cancer care. The Marie-Josée and Henry R. Kravis Cancer Ecosystems Project will tackle the biggest challenges in cancer today, including metastasis, the cause of the vast majority of cancer deaths. Building on the momentum of the past two decades of cancer research, the project will unite specialists across MSK to investigate the complex factors beyond genetics that allow cancer to flourish in the body and to develop treatments to combat its spread.

As Vice Chair of MSK, Chair of the Sloan Kettering Institute, and Chair of the Joint Science Committee of the Boards, Marie-Josée, with her husband, Henry, are helping to shape the future of oncology. “This is a time of extraordinary potential for cancer research,” she says. “I have had the privilege of witnessing MSK lead a revolution in cancer genomics in the past decade, and we are honored to help usher in a new era of ecosystems research that will benefit so many people with cancer.”

Research initiatives are already underway across MSK that use advanced imaging tools and computational techniques to predict where tumors are most likely to spread and to identify environmental factors that spur cancer growth. The Kravis family’s gift will allow MSK to bring new treatments to patients faster than ever before.

“We are profoundly grateful to Marie-Josée and Henry Kravis for their generosity,” says Joan Massagué, Director of the Sloan Kettering Institute and Marie-Josée and Henry R. Kravis Foundation Chair. “Through their partnership, MSK will be able to pursue innovative projects that will help the next generation face every cancer diagnosis with hope and confidence.”

Visit mskcc.org/ecosystems-project to read more about The Marie-Josée and Henry R. Kravis Cancer Ecosystems Project.